1. Home
  2. INAB vs BFRI Comparison

INAB vs BFRI Comparison

Compare INAB & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.44

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Logo Biofrontera Inc.

BFRI

Biofrontera Inc.

HOLD

Current Price

$1.06

Market Cap

13.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INAB
BFRI
Founded
2016
1997
Country
United States
United States
Employees
N/A
94
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.7M
13.2M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
INAB
BFRI
Price
$1.44
$1.06
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$6.00
$2.75
AVG Volume (30 Days)
40.1K
381.2K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$14.36
Revenue Next Year
N/A
$16.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.17
$0.57
52 Week High
$2.73
$1.21

Technical Indicators

Market Signals
Indicator
INAB
BFRI
Relative Strength Index (RSI) 46.12 52.43
Support Level $1.32 $0.77
Resistance Level $1.53 $1.14
Average True Range (ATR) 0.08 0.09
MACD 0.01 -0.00
Stochastic Oscillator 60.31 48.73

Price Performance

Historical Comparison
INAB
BFRI

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

About BFRI Biofrontera Inc.

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.

Share on Social Networks: